The US Food and Drug Administration has authorized 20 ZYN nicotine pouch products to claim they pose a lower risk of certain diseases compared to cigarettes. This decision allows Swedish Match, the manufacturer, to market ZYN as a less harmful alternative for adults switching from smoking, though it does not endorse nicotine pouches as safe or as smoking cessation tools. The nicotine pouch market is rapidly growing, with global sales reaching 23.4 billion units in 2024. Despite their popularity, especially among youth, public health officials remain cautious due to their addictive potential. The FDA’s decision reflects a broader cultural shift towards alternative nicotine products, which now include vapes, e-cigarettes, and heated tobacco devices, all competing in a diverse market for smoking alternatives.
QUESTION: How might the increasing popularity of nicotine pouches among young people impact future public health policies?
The FDA Ruled That ZYN Pouches Are Safer Than Cigarettes. That Doesn’t Mean They’re Safe
